KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Gross Margin (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Gross Margin for 10 consecutive years, with 56.36% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 620.0% year-over-year to 56.36%, compared with a TTM value of 51.79% through Dec 2025, up 305.0%, and an annual FY2025 reading of 51.79%, up 305.0% over the prior year.
  • Gross Margin was 56.36% for Q4 2025 at Teva Pharmaceutical Industries, up from 51.43% in the prior quarter.
  • Across five years, Gross Margin topped out at 56.36% in Q4 2025 and bottomed at 43.21% in Q1 2023.
  • Average Gross Margin over 5 years is 48.55%, with a median of 47.99% recorded in 2021.
  • The sharpest move saw Gross Margin tumbled -443bps in 2022, then skyrocketed 864bps in 2023.
  • Year by year, Gross Margin stood at 50.0% in 2021, then fell by -9bps to 45.57% in 2022, then grew by 19bps to 54.21% in 2023, then fell by -7bps to 50.15% in 2024, then increased by 12bps to 56.36% in 2025.
  • Business Quant data shows Gross Margin for TEVA at 56.36% in Q4 2025, 51.43% in Q3 2025, and 50.34% in Q2 2025.